{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:05:07Z","timestamp":1788109507417,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1093\/ijnp\/pyx033","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T15:11:38Z","timestamp":1496329898000},"page":"613-618","source":"Crossref","is-referenced-by-count":32,"title":["Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder"],"prefix":"10.1093","volume":"20","author":[{"given":"Kathryn M","family":"Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Ceesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hutzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Snavely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Joseph","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"key\n\t\t\t\t20170731025746_CIT0001","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","edition":"4th ed"},{"key":"key\n\t\t\t\t20170731025746_CIT0002","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11920-012-0308-5","article-title":"Is chronic insomnia a precursor to major depression? Epidemiological and biological findings","volume":"14","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"key\n\t\t\t\t20170731025746_CIT0003","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the insomnia severity index as an outcome measure for insomnia research","volume":"2","year":"2001","journal-title":"Sleep Med"},{"key":"key\n\t\t\t\t20170731025746_CIT0004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00406-010-0106-1","article-title":"Validity of the definite and semidefinite questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale","volume":"261","year":"2011","journal-title":"Part I. Eur Arch Psychiatry Clin Neurosci"},{"key":"key\n\t\t\t\t20170731025746_CIT0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2009.09.019","article-title":"Hypocretin\/orexin in arousal and stress","volume":"1314","year":"2010","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t20170731025746_CIT0006","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.5665\/sleep.1996","article-title":"The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia","volume":"35","year":"2012","journal-title":"Sleep"},{"key":"key\n\t\t\t\t20170731025746_CIT0007","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4088\/JCP.09m05663gry","article-title":"The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"71","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0006-3223(95)00188-3","article-title":"Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults","volume":"39","year":"1996","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cmdc.201200025","article-title":"Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties","volume":"7","year":"2012","journal-title":"ChemMedChem"},{"key":"key\n\t\t\t\t20170731025746_CIT0010","first-page":"1","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","volume":"19","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0011","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.euroneuro.2014.05.002","article-title":"Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine","volume":"24","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0012","first-page":"e1001547","article-title":"Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study","volume":"10","year":"2010","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170731025746_CIT0013","first-page":"57","article-title":"A systematic review of augmentation strategies for patients with major depressive disorder","volume":"42","year":"2009","journal-title":"Psychopharmacol Bull"},{"key":"key\n\t\t\t\t20170731025746_CIT0014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.111.005546","article-title":"International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology","volume":"64","year":"2012","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t20170731025746_CIT0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0016","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","year":"2012","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170731025746_CIT0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","year":"2016","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0018","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial","volume":"91","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170731025746_CIT0019","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","year":"2014","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","year":"2014","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20170731025746_CIT0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.npep.2011.07.010","article-title":"Increased numbers of orexin\/hypocretin neurons in a genetic rat depression model","volume":"45","year":"2011","journal-title":"Neuropeptides"},{"key":"key\n\t\t\t\t20170731025746_CIT0022","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","year":"1979","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0023","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.jcp.0000219918.96434.4d","article-title":"An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials","volume":"26","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0024","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neuropharm.2011.04.022","article-title":"Activation of orexin neurons in dorsomedial\/perifornical hypothalamus and antidepressant reversal in a rodent model of depression","volume":"61","year":"2011","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20170731025746_CIT0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000195042.62724.76","article-title":"A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder","volume":"26","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0026","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","year":"2011","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0027","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","article-title":"Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects","volume":"54","year":"2003","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0028","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.psychres.2011.06.004","article-title":"CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls","volume":"190","year":"2011","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t20170731025746_CIT0029","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","article-title":"Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses","volume":"71","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170731025746_CIT0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.smrv.2009.09.003","article-title":"Comorbidity of insomnia and depression","volume":"14","year":"2010","journal-title":"Sleep Med Rev"},{"key":"key\n\t\t\t\t20170731025746_CIT0032","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170731025746_CIT0033","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","article-title":"Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia","volume":"62","year":"2012","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20170731025746_CIT0034","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","year":"2014","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170731025746_CIT0035","first-page":"36","article-title":"Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls","volume":"8","year":"2014","journal-title":"Front Neurosci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/20\/8\/613\/19376737\/pyx033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T15:34:21Z","timestamp":1503588861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article-lookup\/doi\/10.1093\/ijnp\/pyx033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,6,8]]},"published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyx033","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}